These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 30565334

  • 21. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S, Nolte I, Rumstedt K, Sehn M, Raue JF, Weiner F, Treese JS, Beyerbach M, Bach JP.
    BMC Vet Res; 2021 Sep 25; 17(1):310. PubMed ID: 34563187
    [Abstract] [Full Text] [Related]

  • 22. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S, Gordon SG, Fries R, Saunders AB, Sykes KT, Vitt J, Boutet B, Häggström J, Kadotani S, Stack J, Barnett BG.
    J Vet Cardiol; 2023 Dec 25; 50():1-16. PubMed ID: 37913604
    [Abstract] [Full Text] [Related]

  • 23. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease.
    Chetboul V, Serres F, Tissier R, Lefebvre HP, Sampedrano CC, Gouni V, Poujol L, Hawa G, Pouchelon J-.
    J Vet Intern Med; 2009 Dec 25; 23(5):984-94. PubMed ID: 19572913
    [Abstract] [Full Text] [Related]

  • 24. Clinical severity score system in dogs with degenerative mitral valve disease.
    López-Alvarez J, Elliott J, Pfeiffer D, Chang YM, Mattin M, Moonarmart W, Hezzell MJ, Boswood A.
    J Vet Intern Med; 2015 Dec 25; 29(2):575-81. PubMed ID: 25818211
    [Abstract] [Full Text] [Related]

  • 25. Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease.
    Oyama MA, Solter PF, Thorn CL, Stern JA.
    J Vet Cardiol; 2017 Jun 25; 19(3):211-217. PubMed ID: 28478943
    [Abstract] [Full Text] [Related]

  • 26. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N, Wall L, Nolte I, Raue J, Rumstedt K, Pilgram A, Sehn M, Rohn K, Bach JP.
    PLoS One; 2019 Jun 25; 14(10):e0223164. PubMed ID: 31581204
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency.
    Takemura N, Toda N, Miyagawa Y, Asano K, Tejima K, Kanno N, Arisawa K, Kurita T, Nunokawa K, Hirakawa A, Tanaka S, Hirose H.
    J Vet Med Sci; 2009 Jul 25; 71(7):925-9. PubMed ID: 19652480
    [Abstract] [Full Text] [Related]

  • 28. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 25; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 29. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M, Ferasin L, Lamb K, Chiavegato D, Bussadori C, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2021 Aug 25; 36():77-88. PubMed ID: 34118562
    [Abstract] [Full Text] [Related]

  • 30. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study.
    Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP, Lehmkuhl LB, Gordon SG, Kellihan HB, Stepien RL, Lefbom BK, Meier CK, Oyama MA.
    J Vet Cardiol; 2012 Mar 25; 14(1):193-202. PubMed ID: 22366568
    [Abstract] [Full Text] [Related]

  • 31. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration.
    Borgarelli M, Crosara S, Lamb K, Savarino P, La Rosa G, Tarducci A, Haggstrom J.
    J Vet Intern Med; 2012 Mar 25; 26(1):69-75. PubMed ID: 22211523
    [Abstract] [Full Text] [Related]

  • 32. Plasma N-terminal pro-B-type natriuretic peptide concentration in healthy retired racing Greyhounds.
    Couto KM, Iazbik MC, Marín LM, Zaldivar-López S, Beal MJ, Gómez Ochoa P, Couto CG.
    Vet Clin Pathol; 2015 Sep 25; 44(3):405-9. PubMed ID: 25982692
    [Abstract] [Full Text] [Related]

  • 33. Cardiac Troponin I and Amino-Terminal Pro B-Type Natriuretic Peptide in Dogs With Stable Chronic Kidney Disease.
    Pelander L, Häggström J, Ley CJ, Ljungvall I.
    J Vet Intern Med; 2017 May 25; 31(3):805-813. PubMed ID: 28370332
    [Abstract] [Full Text] [Related]

  • 34. Auscultatory, echocardiographic, biochemical, nutritional, and environmental characteristics of mitral valve disease in Norfolk terriers.
    Trafny DJ, Freeman LM, Bulmer BJ, MacGregor JM, Rush JE, Meurs KM, Oyama MA.
    J Vet Cardiol; 2012 Mar 25; 14(1):261-7. PubMed ID: 22364691
    [Abstract] [Full Text] [Related]

  • 35. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.
    Chetboul V, Pouchelon JL, Menard J, Blanc J, Desquilbet L, Petit A, Rougier S, Lucats L, Woehrle F, TEST study investigators.
    J Vet Intern Med; 2017 Nov 25; 31(6):1629-1642. PubMed ID: 28975664
    [Abstract] [Full Text] [Related]

  • 36. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS, Häggström J, Pedersen HD, Hansson K, Järvinen AK, Haukka J, Kvart C.
    J Vet Cardiol; 2014 Sep 25; 16(3):141-54. PubMed ID: 25130405
    [Abstract] [Full Text] [Related]

  • 37. Predictive value of natriuretic peptides in dogs with mitral valve disease.
    Tarnow I, Olsen LH, Kvart C, Hoglund K, Moesgaard SG, Kamstrup TS, Pedersen HD, Häggström J.
    Vet J; 2009 May 25; 180(2):195-201. PubMed ID: 18675567
    [Abstract] [Full Text] [Related]

  • 38. Phosphoproteomics analysis of serum from dogs affected with pulmonary hypertension secondary to degenerative mitral valve disease.
    Sakarin S, Rungsipipat A, Roytrakul S, Jaresitthikunchai J, Phaonakrop N, Charoenlappanit S, Thaisakun S, Surachetpong S.
    PeerJ; 2024 May 25; 12():e17186. PubMed ID: 38708342
    [Abstract] [Full Text] [Related]

  • 39. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J.
    J Vet Cardiol; 2017 Aug 25; 19(4):325-338. PubMed ID: 28734620
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of plasma N-terminal pro-B-type natriuretic peptide concentrations in dogs with and without cardiac disease.
    Ettinger SJ, Farace G, Forney SD, Frye M, Beardow A.
    J Am Vet Med Assoc; 2012 Jan 15; 240(2):171-80. PubMed ID: 22217025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.